SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.


Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
Paper Publishing WeChat
Book Publishing WeChat

Article citations


Dixon, J.A., Gorman, R.C., Stroud, R.E., Bouges, S., Hirotsugu, H., Gorman, J.H., Martens, T.P., Itescu, S., Schuster, M.D., Plappert, T., et al. (2009) Mesenchymal Cell Transplantation and Myocardial Remodeling after Myocardial Infarction. Circulation, 120, S220-S229.

has been cited by the following article:

  • TITLE: Stem Cell Therapy of Ischemic Heart Disease

    AUTHORS: Mikhail Konoplyannikov, Vladimir Kalsin, Alexander Averyanov, Alexander Troitsky

    KEYWORDS: IHD, Remodeling, Regeneration, Stem Cells, MSC, Pre-Conditioning, Paracrine Factors

    JOURNAL NAME: Journal of Biomedical Science and Engineering, Vol.9 No.4, March 29, 2016

    ABSTRACT: Ischemic heart disease (IHD) accelerates death of cardiomyocytes and leads to the onset of cardiac failure. Due to the application of stem cells, there exists a potential for the regeneration of a damaged myocardium. Here we present a brief review of the modern data on the application of various types of stem cells for the IHD therapy. We consider different types of stem cells, which are most preferable for the clinical application, including mesenchymal stem cells, cardiac stem cells, embryonic stem cells, iPS cells and others. In particular, we discuss their advantages and strategies which can be applied in order to boost their regenerative potential, as well as optimization of their delivery. Besides, our review refers to the contemporary achievements in the field of tissue engineering of heart, using both polymer scaffolds and scaffold-free constructs. We also discuss the most prominent known clinical trials on stem cell therapy of ischemic heart disease.